Sign inJoin waitlistJoin the waitlist

Andrew Pecora

Physician · Regional Cancer Care Associates LLC

Credentials: · · · · · ·

History

Regional Cancer Care Associates LLC
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1986–1989
Internal Medicine
1983–1986
Doctor of Medicine
1979–1983

Research

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
The Lancet · 2024 · 686 citations
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
The Journal of Experimental Medicine · 2008 · 398 citations
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
Journal of Clinical Oncology · 2023 · 392 citations

Andre Goy
33 papers
SG
Stuart Goldberg
30 papers
Andrew Ip
15 papers · 2 as a fellow
SR
Scott Rowley
15 papers
Hillard Lazarus
12 papers
David Siegel
11 papers
Michele Donato
11 papers
Noa Biran
10 papers
David Vesole
9 papers
Andrew Jennis
8 papers
Tatyana Feldman
8 papers
MA
Maher Albitar
7 papers

Clinical trials

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Principal investigator · Terminated · Phase 1
Hackensack Meridian Health
2019–2023
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
Study chair · Completed · Phase 2
Hackensack Meridian Health
1999–2001
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Site PI · Recruiting · Phase 2, Phase 3
TuHURA Biosciences, Inc.
2025–2032
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Site PI · Recruiting · Phase 3
Replimune, Inc.
2024–2031